Q32 Bio launches $75M ATM equity offering after exhausting prior $14.2M program

Q32 Bio Inc.

Company sold all $14.2M from prior ATM program; offering terminated as of April 24, 2026.
New prospectus supplement filed for up to $75M in common stock via Cantor Fitzgerald.
Shares offered under effective shelf registration statement (Form S-3, filed April 2025).
Goodwin Procter LLP issued legal opinion on the additional shares (Exhibit 5.1).
No offer or sale in jurisdictions where unregistered or unlawful.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.